Myogen — Investor Presentation (January 2006)
30 slides from Myogen's investor presentation, Jan 9, 2006
Slide 1: Innovative therapies targeting cardiovascular disease
Innovative therapies Ss M targeting cardiovasculardisease Nasdaq: MYOG January 2006
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the matters discussed in this presentation contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the completion and reporting of results from the Company's clinical trials and the potential advantages
Slide 3: Myogen Highlights
Myogen Highlights Therapeutics for Cardiovascular Diseases Late-stage Product Pipeline Ambrisentan for PAH (positive Phase 3 results - Dec 2005) Darusentan for RHTN (positive Phase 2b results - Aug 2005) Commercial Rights Retained Integrated Target and Drug Discovery Platform Drug Discovery and Deve
Slide 4: Management Team
Management Team J. William Freytag, PhD President & CEO Michael Bristow, MD, PhD Chief Medical & Science Officer Michael Gerber, MD SVP Clinical Development & Regulatory Affairs Richard Gorczynski, PhD SVP Research & Development John Julian SVP Commercial Development Joseph Turner SVP Finance & CFO
Slide 5: Business Strategy
Business Strategy Selectively in-license or acquire compounds in clinical development for which we have a unique ability to add value Leverage our understanding of heart failure at the molecular level in the discovery and development of disease modifying therapeutics
Slide 6: Myogen Product Portfolio
Myogen Product Portfolio Myogen Product Potential Indication Phase1 Phase? Phase3 Marketed Perfan® ILV. Acute Decompensated (.v.enoximone) Heart Failure Hypertension Resistant Darusentan ngreviersiem Cardiac Hypertrophic Heart Failure Discovery Signaling
Slide 7: Myogen Product Portfolio
Myogen Product Portfolio Myogen Product Potential Indication Preclinical Phase1 Phase? Phase3 Marketed Perfan® |LV. Acute 2 EES > v.enoximone) Heart Failure Darusentan Resistant Hypertension Cardiac Hypertrophic Heart Failure Discovery Signaling
Slide 8: Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) Severely debilitating, life-threatening disease Estimated 200,000 individuals worldwide have PAH Multiple etiologies Primary pathogenesis is pulmonary endothelial cell dysfunction or injury leading to: Vasoconstriction Smooth-muscle cell and endothelial cell pro
Slide 9: PAH Therapies (estimated 2004 sales)
PAH Therapies (estimated 2004 sales) ERAs Prostacyclin Analogs PDE-5 Inhibitors Other Sales 372.89 311.91 2 5.671 Total: $690.5 million Endothelin Receptor Antagonists 54% Prostacyclin Analogs 45% CCBs, Vit. K Antagonists, Diuretics 1% PDE-5 Inhibitors 0% Sources: Decision Resources PAH Cardium (2/2
Slide 10: Ambrisentan
Ambrisentan ETA-selective High potency and oral bioavailability Long half-life (9-15 hours) No significant p450 induction or inhibition No active metabolite - excreted in feces Linear pharmacokinetics Patent protection through 2015 Orphan drug designation in US and EU Ambrisentan is a second-generat
Slide 11: Ambrisentan Potential Advantages
Ambrisentan Potential Advantages Efficacy Delay in clinical worsening Robust improvements in exercise capacity Early on-set and durable efficacy Comparable efficacy in Class II and Class III Dose flexibility Safety profile and ease of use Once daily dosing No apparent drug-drug interactions with oth
Slide 12: Ambrisentan Clinical Program
Ambrisentan Clinical Program Phase 1 Phase 2 Phase 3 Healthy Volunteers Single Dose 63 subjects Healthy Volunteers Multiple Dose 30 subjects, 10 days AMB-220 Dose-Ranging 64 subjects, 12 wk Open-label Extension 12 wk Phase 2 Long-term AMB-220-E Phase 3 AMB-320 (ARIES-1) Primarily U.S. 202 subjects,
Slide 13: ARIES-2 Results
ARIES-2 Results Achieved primary efficacy endpoint: 5 mg of ambrisentan improved the placebo-corrected mean 6MWD by 59.4 meters (p = 0.0002) 2.5 mg of ambrisentan improved the placebo-corrected mean 6MWD by 32.3 meters (p = 0.0219) Improvements in time to clinical worsening compared to placebo were
Slide 14: Ambrisentan demonstrated significant efficacy
50 60 - -20 - -10 0 10 20 30 40 Change in 6MWD (meters) Bosentan BREATHE-1 n = 74 Sitaxsentan STRIDE-1&2 n= 55/61 - -13 +22 100 mg 100 mg +22 2.5 mg 5 mg - -8 Ambrisentan ARIES-2 n= 64/63 Ambrisentan demonstrated significant efficacy 1- Myogen Press Release, December 12, 2005. 2- FDA Briefing Docume
Slide 15: Ambrisentan demonstrated significant efficacy (placebo-corrected 6MWD)
50 60 0 10 20 30 40 Placebo-corrected ?6MWD (m) +35 100 mg qd 100 mg qd Ambrisentan demonstrated significant efficacy 1- Myogen Press Release, December 12, 2005. 2- FDA Briefing Document on Tracleer for CardioRenal Advisory Panel, August 10, 2001 and Tracleer Product Labeling. 3- Barst et al., Sitax
Slide 16: Ambrisentan Phase 2 Long-term Data
*p < 0.0001 36* 47* 37* 52* 55* 38* 0 20 40 60 80 Week 12 Feb 2005 Change in 6MWD (meters) All Subjects AMB Therapy AMB Monotherapy Mean exposure = 1.7 years Maximum exposure = 2.3 years Olschewski et al ERS 2005 Ambrisentan Phase 2 Long-term Data
Slide 17: Ambrisentan apparent survival benefit
Observed Survival NIH Predicted Survival 50 60 70 80 90 100 0 200 400 600 800 Days Event-free patients (%) 1-yr : 92% vs. 73% 2-yr : 89% vs. 62% Olschewski et al ERS 2005 Ambrisentan apparent survival benefit IPAH Patients
Slide 18: LFT Rescue Study (AMB-222)
LFT Rescue Study (AMB-222) 36 patients IPAH, FPAH, or PAH associated with CTD, CHD, anorexigen use, or HIV Patients who previously discontinued bosentan, sitaxsentan, or both, due to AST / ALT > 3xULN Ambrisentan 2.5 mg for 4 weeks, 5 mg thereafter (open-label) Long-term treatment with ambrisentan a
Slide 19: Ambrisentan Potential Advantages
Ambrisentan Potential Advantages Efficacy Delay in clinical worsening Robust improvements in exercise capacity Early on-set and durable efficacy Comparable efficacy in Class II and Class III Dose flexibility Safety profile and ease of use Once daily dosing No apparent drug-drug interactions with oth
Slide 20: Prevalence of Resistant Hypertension
Prevalence of Resistant Hypertension Prevalent Population (2005)* (~65 million in the US) Diagnosed & Treated Population* (~39 million in the US) ~10-30% of Patients on Therapy Do Not Reach Target BP (4-12 million)* * Myogen, Inc. estimates based on syndicated data sources, claims data (2003,2004) a
Slide 21: Resistant Hypertension
Resistant Hypertension Individuals with uncontrolled high blood pressure are at significantly greater risk for serious cardiovascular and renal complications JNC 7 defines resistant hypertension as: "... the failure to achieve goal blood pressure in patients who are adhering to full doses of an appr
Slide 22: Darusentan Characteristics
Darusentan Characteristics ETA-selective Potential once daily dosing Approximately 1,500 patients studied in prior trials Potent anti-hypertensive properties Well tolerated No evidence of liver toxicity Darusentan is a second-generation ERA with a large safety database
Slide 23: Darusentan Phase 2b Trial Design
10 mg 50 mg 100 mg 150 mg 300 mg Study Week - -2 0 4 6 Randomization Placebo Treatment Period - -4 Screening Period Placebo Run-in Withdrawal 10 8 2 100 mg 11 12 Final Safety Visit P P 115 patients randomized 2:1 Darusentan Phase 2b Trial Design
Slide 24: Darusentan Phase 2b Results
Darusentan Phase 2b Results Achieved primary efficacy endpoint: - -11.6 mmHg reduction in systolic BP (p = 0.02) Secondary endpoints also achieved, including: - -5.8 mmHg reduction in diastolic BP (p = 0.004) Clinically meaningful reductions in systolic and diastolic b.p. at earlier time points at l
Slide 25: Darusentan Next Steps
Darusentan Next Steps Finalize Phase 3 clinical development program End-of-Phase 2 meeting with FDA held in Oct'05 Further interactions with regulatory agencies (US & European) in Q1 Evaluating Special Protocol Assessment Initiate global Phase 3 program Q2 2006
Slide 26: Integrated Target & Drug Discovery Platform
Integrated Target & Drug Discovery Platform Intact human heart gene expression Human cardiomyocyte culture Molecular Targets for Heart Failure Assays, High Throughput Screening & Drug Discovery Validation Cardiac signaling pathways Cardiogenomics Cardioproteomics Fetal Gene Program Heart Tissue Bank
Slide 27: Drug Discovery and Development Partnership with Novartis
Drug Discovery and Development Partnership with Novartis Broad strategic partnership in heart muscle disease Expanded in Q2 2005 to include HDAC inhibitor program Annual research funding to Myogen for 3 years, annually renewable thereafter Significant commitment of Novartis resources Success milesto
Slide 28: Selected Financial Information
Selected Financial Information
Slide 29: 2005 Review
2005 Review Completed ARIES-2 enrollment July 21 Darusentan Phase 2b results August 18 Completed $125M financing September 21 ARIES-1 target enrollment November 10 ARIES-2 results December 12
Slide 30: 2006 Guidance (as of January 9, 2006)
2006 Guidance (as of January 9, 2006)1 AMB-222 Results Feb ARIES-1 Results Q2 Initiate Darusentan Phase 3 Q2 Ambrisentan NDA Submission Q4 1- The guidance was effective on the date it was issued and it is our policy not to publicly or privately confirm prior guidance except in a widely disseminated